Multiple Sclerosis Clinical Trial
The MS-LINK™ Outcomes Study
Summary
The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the study (currently 3 years), unless the participant chooses to withdraw from the study. Collection of participant's medical history, including MS and treatment history, will be automated through extraction from the participant's electronic medical record (EMR) and other health information systems (for example, radiology). Participants will complete patient-reported outcomes (PROs) and other health-related information digitally. Participating participants will have access to their own data in an ongoing manner via a web-based Participant Portal.
Eligibility Criteria
Inclusion Criteria:
Participants willing and able to provide written informed consent
Participants willing to be contacted while participating in the study for recruitment into sub-studies that may be relevant to them
Participants willing and able to complete PROs on a monthly basis and document events of interest as they occur
Participants willing to participate in additional follow up at the site for at least three years
Exclusion Criteria:
Unable to complete questionnaires in English
Unable to consistently access the Internet
Participants participating in interventional clinical drug trials at baseline
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 9 Locations for this study
Birmingham Alabama, 35209, United States
Washington District of Columbia, 20057, United States
Atlanta Georgia, 30327, United States
Boston Massachusetts, 02215, United States
Owosso Michigan, 48867, United States
Omaha Nebraska, 68198, United States
Oklahoma City Oklahoma, 73104, United States
Austin Texas, 78759, United States
San Antonio Texas, 78229, United States
How clear is this clinincal trial information?